EMA Validation of ENHERTU Breast Cancer Treatme...

By HEOR Staff Writer

February 20, 2026

EMA Validates ENHERTU Breast Cancer Treatment Variation The European Medicines Agency (EMA) has validated a Type II Variation marketing authorization application for ENHERTU br...
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
Revised MenACWY Vaccination Strategy for Adolescents in Germany
Genotype ECG Prediction
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL T...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...